By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Corus Pharma, Inc. 

A subsidiary of Gilead Sciences
2025 First Avenue, Suite 800
Seattle  Washington  98121  U.S.A.
Phone: 206-728-5090 Fax:

Corus Pharma is a biopharmaceutical company committed to developing and commercializing products for severe respiratory and infectious diseases that can help provide improved health and superior quality of life. More information about Corus Pharma may be found at

We are located in the heart of downtown Seattle, just one block from the historic Pike Place Market. We offer competitive compensation and health benefits, casual work environment, 401(k), stock options, parking and health club subsidy.

Last Updated: 12-15-04

Key Statistics

Ownership: Private

Web Site: Corus Pharma, Inc.


Company News
Corus Pharma, Inc. Reports Positive Topline Results Showing Clear Signal Of Clinical Benefit With Resunab (JBT-101) In Phase 2 Study In Systemic Sclerosis 12/29/2016 12:00:55 PM
Gilead Sciences (Foster City, CA) (GILD) Completes Acquisition Of Corus Pharma, Inc. 8/14/2006 10:56:31 AM
Gilead Sciences (Foster City, CA) (GILD) Exercises Option To Acquire Corus Pharma, Inc. For $365 Million 8/3/2006 12:56:44 PM
The Day In Review: Gilead Sciences (Foster City, CA) (GILD) Pays $365 Million For Corus Pharma, Inc. 7/20/2006 4:52:19 PM
Gilead Sciences (Foster City, CA) (GILD) Agrees To Exercise Its Option To Acquire Corus Pharma, Inc. For $365 Million 7/20/2006 10:37:03 AM
Gilead Sciences (Foster City, CA) (GILD) Invests $25 Million In Corus Pharma, Inc. 4/12/2006 4:44:14 PM
Corus Pharma, Inc. Withdraws IPO Plan 2/17/2006 1:31:35 PM
PARI Aerosol Research Institute's Formulation Work And eFlow Featured In Corus Pharma, Inc.'s Positive Phase II Trial Results10/19/2005 5:11:53 PM
Corus Pharma, Inc. Announces Positive Phase II Results For Cystic Fibrosis Drug10/19/2005 5:11:51 PM
Corus Pharma, Inc. Hires Chief Commercial Officer 10/19/2005 5:11:49 PM